JOURNAL ARTICLE

Lipid‐modifying statins, fibrates reduce mortality in schizophrenia patients.

  • Published In: Brown University Psychopharmacology Update, 2024, v. 35, n. 9. P. 1 1 of 2

  • Database: Academic Search Ultimate 2 of 2

Abstract

A nationwide cohort study conducted in Taiwan has found that lipid‐modifying agents, particularly statins and fibrates, reduce mortality risk in patients with schizophrenia. The reduced risk was apparent for both all‐cause and natural‐cause mortality, the investigators reported. Study results were published online May 16, 2024, in The British Journal of Psychiatry. [ABSTRACT FROM AUTHOR]

Additional Information

  • Source:Brown University Psychopharmacology Update. 2024/09, Vol. 35, Issue 9, p1
  • Document Type:Article
  • Subject Area:Health and Medicine
  • Publication Date:2024
  • ISSN:1068-5308
  • DOI:10.1002/pu.31199
  • Accession Number:178814653
  • Copyright Statement:Copyright of Brown University Psychopharmacology Update is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Looking to go deeper into this topic? Look for more articles on EBSCOhost.